The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling

Annual Review of Biochemistry

Volumn 80, Issue , 2011, Pages 769-795

  Dar, Arvin C ^a   Shokat, Kevan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

drug discovery; kinase inhibitor; protein kinases; signal transduction

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; A 443654; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LITHIUM; NILOTINIB; PAZOPANIB; PD 318088; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; RIBONUCLEASE; SORAFENIB; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIOINFORMATICS; BREAST CANCER; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NEOPLASM; PANCREAS CANCER; PARASITE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 79959476700     PISSN: 00664154     EISSN: 00664154     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-090308-173656     Document Type: Article

References (75)

1. Cohen P. 2002. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:309-315. (Pubitemid 37361447)
2. Liu Y, GrayNS. 2006. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2:358-364. (Pubitemid 43936934)
3. ShenK, Hines AC, Schwarzer D, Pickin KA, Cole PA. 2005. Protein kinase structure and function analysis with chemical tools. Biochim. Biophys. Acta 1754:65-78. (Pubitemid 41797688)
4. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. 1986. Staurosporine, a potent inhibitor of phospholipid/Ca++-dependent protein kinase. Biochem. Biophys. Res. Commun. 135:397-402. (Pubitemid 16049425)
5. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26:127-132.
6. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. 1997. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4:796-801.
7. Graziani Y, Erikson E, Erikson RL. 1983. The effect of quercetin on the phosphorylation activity of the rous sarcoma virus transforming gene product in vitro and in vivo. Eur. J. Biochem. 135:583-589. (Pubitemid 13013793)
8. Lyall RM, Zilberstein A, Gazit A, GilonC, Levitzki A, Schlessinger J. 1989. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 264:14503-9. (Pubitemid 19214287)
9. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-745.
10. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. 1998. Conversion of SB 203580-insensitiveMAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem. Biol. 5:321-328. (Pubitemid 28309985)
11. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, et al. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229-233.
12. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, et al. 1996. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:695-701.
13. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, et al. 1994. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093-095. (Pubitemid 24293076)
14. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. 1995. A synthetic inhibitor of the mitogenactivated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686-689.
15. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-494.
16. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, et al. 2004. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11:1192-197.
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566.
18. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, et al. 1998. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280:69-77. (Pubitemid 28169082)
19. Schindler T, BornmannW, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-942.
20. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
21. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. 2007. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15:299-311. (Pubitemid 46366721)
22. Dar AC, Lopez MS, Shokat KM. 2008. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem. Biol. 15:1015-022.
23. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, et al. 2009. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69:2384-392.
24. Simard JR, Kl ̈ uter S, Gr̈ utter C, Getlik M, Rabiller M, et al. 2009. A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol. 5:394-396.
25. Hubbard SR. 2002. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. 12:735-741. (Pubitemid 36009489)
26. Klein PS, Melton DA. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93:8455-459. (Pubitemid 26269579)
27. Ryves WJ, Dajani R, Pearl L, Harwood AJ. 2002. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290:967-72. (Pubitemid 34687456)
28. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408:297-315.
29. Williams RS, Cheng L, Mudge AW, Harwood AJ. 2002. A common mechanism of action for three mood-stabilizing drugs. Nature 417:292-295. (Pubitemid 34534711)
30. King J, Keim M, TeoR, WeeningKE, Kapur M, et al. Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes. PLoS ONE 5:e11151.
31. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, et al. 2000. A chemical switch for inhibitorsensitive alleles of any protein kinase. Nature 407:395-401.
32. Eyers PA, Van Den IP, Quinlan RA, Goedert M, Cohen P. 1999. Use of a drug-resistantmutant of stressactivated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 451:191-196. (Pubitemid 29231947)
33. Scutt PJ, Chu ML, Sloane DA, Cherry M, Bignell CR, et al. 2009. Discovery and exploitation of inhibitorresistant aurora and polo kinase mutants for the analysis of mitotic networks. J. Biol. Chem. 284:15880-893.
34. Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem. Biol. 5:563-576.
35. Knight ZA, Shokat KM. 2007. Chemical genetics: where genetics and pharmacology meet. Cell 128:425-30. (Pubitemid 46198904)
36. Cohen MS, Zhang C, Shokat KM, Taunton J. 2005. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308:1318-321. (Pubitemid 40746129)
37. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, et al. 1998. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95:12022-027. (Pubitemid 28460532)
38. Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD. 2010. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 465:359-362.
39. Knighton DR, Zheng JH, Ten-Eyck LF, Ashford VA, Zuong NH, et al. 1991. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate regulated protein kinase. Science 253:407-414. (Pubitemid 21917165)
40. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. 1996. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331. (Pubitemid 26260452)
41. Zhang X, Pickin KA, Bose R, JuraN, Cole PA, Kuriyan J. 2007. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450:741-744. (Pubitemid 350207680)
42. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-149. (Pubitemid 43866200)
43. Riese DJ 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF. 1995. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell Biol. 15:5770-6.
44. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 107:7692-697.
45. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. 2009. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 106:21608-613.
46. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-934. (Pubitemid 35425239)
47. Zhang J, Adrían FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. 2010. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463:501-6.
48. Barnett SF, Defeo-JonesD, Fu S, Hancock PJ, Haskell KM, et al. 2005. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385:399-408. (Pubitemid 40165072)
49. Calleja V, Laguerre M, Parker PJ, Larijani B. 2009. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 7:e17.
50. Green CJ, Goransson O, Kular GS, Leslie NR, Gray A, et al. 2008. Use of Akt inhibitor and a drugresistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J. Biol. Chem. 283:27653-667.
51. Liu P, Cheng H, Roberts TM, Zhao JJ. 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8:627-644.
52. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, et al. 2009. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol. 5:758-764.
53. Wei L, Gao X, Warne R, Hao X, Bussiere D, et al. 2010. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorg. Med. Chem. Lett. 20:3897-902.
54. Papa FR, Zhang C, Shokat K, Walter P. 2003. Bypassing a kinase activity with an ATP-competitive drug. Science 302:1533-537. (Pubitemid 37475689)
55. Korennykh AV, Egea PF, Korostelev AA, Finer-Moore J, Zhang C, et al. 2009. The unfolded protein response signals through high-order assembly of Ire1. Nature 457:687-693.
56. Cameron AJM, Escribano C, Saurin AT, Kostelecky B, Parker PJ. 2009. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16:624-630.
57. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, et al. 2005. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4:977-986. (Pubitemid 40909080)
58. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, et al. 2009. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5:484-493.
59. Srivastava J, Procyk KJ, Iturrioz X, Parker PJ. 2002. Phosphorylation is required for PMA- and cell-cycleinduced degradation of protein kinase Cdelta. Biochem. J. 368:349-355. (Pubitemid 35463439)
60. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, et al. 1999. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6:559-568. (Pubitemid 29380770)
61. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, et al. 2009. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27:15s.
62. Poulikakos PI, Zhang C, Bollag G, Shokat KM, RosenN. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430.
63. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435.
64. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
65. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158. (Pubitemid 46398669)
66. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867. (Pubitemid 38410730)
67. Kornev AP, Taylor SS. 2009. Pseudokinases: functional insights gleaned from structure. Structure 17:5-7.
68. Fukuda K, Gupta S, Chen K, Wu C, Qin J. 2009. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol. Cell 36:819-830.
69. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. 2009. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17:128-138.
70. Zeqiraj E, Filippi BM, DeakM, Alessi DR, van Aalten DM. 2009. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326:1707-711.
71. Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, et al. 2008. CASK functions as a Mg2+- independent neurexin kinase. Cell 133:328-339. (Pubitemid 351508303)
72. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. 2006. Emerging roles of pseudokinases. Trends Cell Biol. 16:443-452. (Pubitemid 44293399)
73. Rajakulendran T, Sicheri F. Allosteric protein kinase regulation by pseudokinases: insights from STRAD. Sci. Signal. 3:pe8.
74. ApselB, Blair JA, GonzalezB, NazifTM, Feldman ME, et al. 2008. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4:691-699.
75. Knight ZA, Lin H, Shokat KM. 2010. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10:130-37